MAM
ADMA icon

Marquette Asset Management’s ADMA Biologics ADMA Stock Holding History

Marquette Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-55
Closed -$496 – 834
2026
Q1 		$496 Buy
55
+29
+112% +$458 ﹤0.01% 759
2025
Q4 		$475 Buy
+26
New +$438 ﹤0.01% 676

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marquette Asset Management's ADMA Position: Q2 2026 in Review

Marquette Asset Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 55 shares — an estimated $496 sold.

Marquette Asset Management first reported a position in ADMA in Q4 2025 and held it in 2 quarters. The position peaked at $496 in Q1 2026. 131 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Marquette Asset Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Marquette Asset Management sold 55 ADMA Biologics shares in Q2 2026, an estimated $496.
  • Marquette Asset Management first reported a position in ADMA Biologics in Q4 2025 and held it in 2 quarters.
  • Marquette Asset Management's ADMA Biologics position peaked at $496 in Q1 2026.
  • 131 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.